Key result
In rats with CHF, CGS 26303 decreased preload and afterload, increased cardiac output, and diminished LV hypertrophy, dilatation, and cardiac fibrosis compared to CGS 24592.
Why the study?
Does dual ECE-NEP inhibition with CGS 26303 improve hemodynamics and prevent cardiac remodeling in rats with congestive heart failure compared to selective NEP inhibition?
Does dual ECE-NEP inhibition with CGS 26303 improve hemodynamics and prevent cardiac remodeling in rats with congestive heart failure compared to selective NEP inhibition?
Long-term dual ECE-NEP inhibition improves cardiac function and attenuates remodeling in a rat model of heart failure, suggesting potential therapeutic benefits in human CHF.
No takes yet. Share an insight, caveat, or question.
Dual ECE-NEP inhibition shows promise in rat CHF models; leaves open translation to human therapy.
Mulder et al. (2004) studied Congestive heart failure. CGS 26303 (dual ECE-NEP inhibitor) vs. CGS 24592 (selective NEP inhibitor) was evaluated on Systemic and left ventricular hemodynamics and LV remodeling. In rats with CHF, CGS 26303 decreased preload and afterload, increased cardiac output, and diminished LV hypertrophy, dilatation, and cardiac fibrosis compared to CGS 24592.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: